SCHEMBL6042277

SCHEMBL6042277

COCCCN1CCN(C[O])CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.40
MAPT P10636 2/20 0.38
POLB P06746 1/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
SLC29A1 Q99808 2/20 0.37
HRH2 P25021 2/20 0.36
HRH1 P35367 2/20 0.36
HSD11B1 P28845 1/20 0.36
MEN1 O00255 1/20 0.35
ABCC4 O15439 1/20 0.35
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
CHRM3 P20309 1/20 0.35
HTR2A P28223 1/20 0.35
MAPK1 P28482 1/20 0.35
SLC6A4 P31645 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10924619 0.89 ALDH1A1 (0.39) DRD2ALDH1A1KDM4ESLC29A1CYP2D6
SCHEMBL11575418 0.89
SCHEMBL6945807 0.87 ALDH1A1 (0.38) DRD2MAPTPOLBALDH1A1KDM4E
SCHEMBL8880908 0.87 ALDH1A1 (0.38) DRD2MAPTPOLBALDH1A1KDM4E
SCHEMBL6043320 0.85 ALDH1A1 (0.37) DRD2MAPTALDH1A1KDM4ESLC29A1
SCHEMBL10930283 0.84 HSD11B1 (0.42) ALDH1A1KDM4ESLC29A1HSD11B1MAPK1
SCHEMBL6042281 0.83 SLC29A1 (0.37) DRD2MAPTPOLBALDH1A1KDM4E
SCHEMBL25960101 0.83 ALDH1A1 (0.35) DRD2ALDH1A1KDM4ESLC29A1HSD11B1
SCHEMBL84799 0.82 HRH3 (0.46) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL11574905 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides ELAN PHARMACEUTICALS, INC. 2006-04-27 US disclosed
WO-2003103652-A1 METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES ELAN PHARMACEUTICALS, INC. (US) 2003-12-18 WO disclosed
US-5641778-A EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-06-24 US disclosed
EP-0716077-A1 Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors CIBA-GEIGY AG (CH) 1996-06-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides APP, BACE1, BACE2 DRD2 1382/4885MAPT 282/4885POLB 3076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.